CLINICAL TRIALS PROFILE FOR LENALIDOMIDE

505(b)(2) Clinical Trials for Lenalidomide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00974233 ↗	Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL	Completed	Celgene Corporation	Phase 2	2009-10-01	The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination	NCT00974233 ↗	Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL	Completed	University of Wisconsin, Madison	Phase 2	2009-10-01	The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination	NCT01245673 ↗	Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma	Completed	University of Pennsylvania	Phase 2	2011-05-10	One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells. A second purpose is to find out how well this combination of immune system treatments is able to control the myeloma.
New Combination	NCT01755975 ↗	Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma	Active, not recruiting	Biologics, Inc.	Phase 1/Phase 2	2012-12-01	The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.

All Clinical Trials for Lenalidomide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00031941 ↗	CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy	Completed	National Cancer Institute (NCI)	Phase 1	2002-04-01	RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
NCT00031941 ↗	CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy	Completed	National Institutes of Health Clinical Center (CC)	Phase 1	2002-04-01	RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
NCT00036894 ↗	CC-5013 in Treating Patients With Recurrent Glioma	Completed	National Cancer Institute (NCI)	Phase 1	2002-03-01	RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
NCT00046735 ↗	Phase 1 Study OF CDC-501 in Patients With Solid Tumors	Completed	Celgene	Phase 1	2002-06-01	To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.

Clinical Trial Conditions for Lenalidomide

Condition Name

Condition Name for Lenalidomide
Intervention	Trials
Multiple Myeloma	408
Chronic Lymphocytic Leukemia	46
Lymphoma	41
Diffuse Large B-Cell Lymphoma	35

Condition MeSH

Condition MeSH for Lenalidomide
Intervention	Trials
Multiple Myeloma	589
Neoplasms, Plasma Cell	528
Lymphoma	300
Leukemia	126

Clinical Trial Locations for Lenalidomide

Trials by Country

Trials by Country for Lenalidomide
Location	Trials
China	317
Poland	83
Netherlands	75
Austria	71
Greece	67

Trials by US State

Trials by US State for Lenalidomide
Location	Trials
New York	244
California	219
Texas	212
Florida	170
Ohio	169

Clinical Trial Progress for Lenalidomide

Clinical Trial Phase

Clinical Trial Phase for Lenalidomide
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	21
PHASE2	57

Clinical Trial Status

Clinical Trial Status for Lenalidomide
Clinical Trial Phase	Trials
Completed	378
Recruiting	296
Active, not recruiting	186

Clinical Trial Sponsors for Lenalidomide

Sponsor Name

Sponsor Name for Lenalidomide
Sponsor	Trials
Celgene Corporation	272
National Cancer Institute (NCI)	182
Celgene	161

Sponsor Type

Sponsor Type for Lenalidomide
Sponsor	Trials
Other	1355
Industry	994
NIH	194

Lenalidomide: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 26, 2026

What is the current clinical trial landscape for lenalidomide?

Lenalidomide remains a foundational immunomodulatory drug across multiple oncology settings, anchored by long-established label indications for hematologic malignancies. Trial activity continues primarily in three areas: (1) earlier-line regimens, (2) combination strategies to improve depth and durability of response, and (3) regimen refinements designed to reduce toxicity or treatment burden while preserving efficacy.

Trial focus by disease area (high-level)

Disease area	Common trial themes	Typical endpoints used
Multiple myeloma	Triplet and doublet combinations with proteasome inhibitors, anti-CD38 antibodies, and other IMiD backbone variants; earlier-line expansion	MRD negativity rates, PFS, OS, response depth, safety
MDS and lower-risk myeloid disorders	IMiD-based combinations and schedule optimization	Transfusion independence, hematologic improvement, PFS/OS (where applicable)
Lymphoma and other hematologic cancers	Combination regimens and sequencing strategies	ORR, PFS, OS, duration of response

What to watch in ongoing trials

Clinical programs for lenalidomide generally track label-proven mechanisms: cereblon-mediated IMiD effects (anti-tumor activity plus immunomodulation). Current development patterns favor combinations because they typically generate higher response rates and deeper remissions, which are the main drivers of downstream market performance (faster conversion of treatment lines into standardized-of-care use). The risk-management ecosystem (notably thrombosis and second primary malignancy risk monitoring) also shapes trial design via prophylaxis requirements and monitoring intensity.

Which lenalidomide formulations and brands dominate the market?

Lenalidomide is marketed globally under branded names and is supported by extensive regulatory history. The key business point: the reference product and its lifecycle management determine pricing power, access, and formulary adoption across major geographies.

Market region	Primary brand(s) historically used	Notes relevant to market dynamics
US	Revlimid (Celgene/BMS)	Consolidated historical penetration; generic and biosimilar competition impacts net price
EU	Revlimid and authorized generics depending on country	Tendering and national reimbursement strongly affect uptake
Japan and other APAC	Local approvals and commercial presence	Regional reimbursement schedules drive volume shifts

How large is the lenalidomide market and what are the segmentation drivers?

Lenalidomide demand is driven by:

1. Multiple myeloma incidence and treatment intensity in US and EU markets.
2. Use across multiple lines of therapy (including earlier lines where trials support adoption).
3. Path-to-market effects from patent expiry and generic entry, which pressure gross-to-net pricing.
4. Payer dynamics: prior authorization, step therapy, and copay support programs.

Market structure: where revenue comes from

Segment	Primary indication contributors	Why it matters for revenue
Multiple myeloma	Frontline and relapsed regimens	The largest and most consistent use case for IMiD-based therapy
MDS and related myeloid settings	MDS with del(5q) and other relevant categories depending on label	Adds incremental demand but typically smaller than myeloma
Other hematologic malignancies	Lymphoma and other off/on-label combination use where supported	Depends on evidence maturity and reimbursement acceptance

What is the realistic projection for growth: base, downside, and upside?

Projections for lenalidomide should be read through two opposing forces:

• Growth engine: expanding utilization in earlier lines and combination regimens that improve response durability.
• Price erosion: generic competition and biosimilar-type dynamics for small-molecule generics typically compress net price and limit revenue growth even if volume rises.

Projection logic (commercial, not epidemiologic)

• In periods of generic adoption, volume growth often offsets partially but not fully price compression.
• The fastest share gains occur when trials establish superior outcomes and regimen placement shifts upward in the line-of-therapy ladder.
• Net sales track gross pricing less rebates and discounts; the most material factor becomes gross-to-net deterioration following competitive entry.

Scenario framework (directional projection)

Scenario	Assumptions	Likely market outcome
Base	Modest utilization expansion in myeloma + persistent price pressure from generic competition	Flat-to-low growth in net value despite volume stability or mild rise
Upside	More trial-readout driven guideline adoption and improved sequencing economics	Volume expansion outweighs some price erosion, producing stronger net growth
Downside	Faster price compression and slower conversion of new evidence into covered regimens	Net sales decline or prolonged stagnation

What do the latest regulatory and label foundations imply for future demand?

Lenalidomide is supported by a mature label history in multiple myeloma and MDS, which matters for projections because:

• Formularies and reimbursement pathways already exist.
• Clinical adoption is less dependent on each new trial readout than it is for newer agents.
• Combination regimens often build on existing safety management workflows (prophylaxis, monitoring, risk mitigation programs).

In practice, the key demand lever is not label breadth alone, but how trial outcomes translate into guideline placement and payer coverage.

Where does lenalidomide face competitive substitution risk?

Competitive substitution is driven by:

• Newer classes in myeloma (e.g., next-generation immunotherapies and BCMA-directed approaches) that can shift treatment paradigms, particularly later-line.
• IMiD alternatives (within the same mechanism family) and combination regimens that substitute IMiDs with other active backbones in certain patient subgroups.
• Generic price advantage for lenalidomide itself: it lowers patient and payer cost, which can reduce switching away from the molecule unless efficacy differences are meaningful.

What is the investment-grade view of risk and defensibility?

Lenalidomide’s defensibility is primarily commercial and operational rather than purely patent-based:

• Established clinical use and manufacturing at scale.
• Broad clinician familiarity and standardized safety management.
• Integration into combination regimens that span lines of therapy.

The main investment risk is the predictability of price erosion after competitive entry and the speed at which payers reprice.

---

Clinical Trials Update: What’s driving the pipeline narrative?

Most new clinical value for lenalidomide comes from combinations and sequencing. Programs that demonstrate:

• higher MRD-negative rates,
• longer PFS,
• better tolerability or lower treatment discontinuation, tend to translate into guideline updates and payer coverage, which then drives durable demand.

Practical read-through for business planning

• Track trial readouts by the magnitude of response depth and durability, not only ORR.
• Prioritize evidence that supports line-of-therapy migration (earlier use) because that increases cumulative eligible patient population.
• Weight safety signals that affect continuity of therapy and prophylaxis cost.

---

Key Takeaways

• Lenalidomide’s clinical development remains concentrated in multiple myeloma and IMiD-driven combination strategies, with trial value centered on response depth, MRD, and PFS.
• Market dynamics are dominated by two forces: utilization expansion through earlier-line adoption versus net price compression from generic competition.
• Projections should be scenario-based: base case points to flat-to-low net growth as price erosion likely offsets volume gains.
• Competitive substitution risk exists from next-generation myeloma therapies, but lenalidomide’s cost position and clinical embeddedness typically constrain share loss.

---

FAQs

1. What is lenalidomide primarily used for commercially?
   Multiple myeloma is the dominant commercial indication, with additional demand from myeloid disorders such as MDS depending on label and country reimbursement structures.

2. Why do combinations matter more than monotherapy trials for lenalidomide?
   Real-world prescribing patterns favor regimens that improve durability (PFS/OS) and response depth; combinations influence line placement and payer coverage.

3. What is the main driver of net sales changes for lenalidomide?
   Net pricing erosion following generic entry and gross-to-net deterioration are typically more decisive than incremental clinical adoption in the near term.

4. How does safety monitoring affect trial and market outcomes?
   Thrombosis risk management, infection monitoring, and surveillance for second malignancies shape dosing continuity, discontinuation rates, and real-world persistence.

5. What endpoints most influence market adoption after a trial readout?
   MRD negativity, PFS, and overall safety/treatment discontinuation profiles generally drive guideline and coverage decisions.

---

References

[1] European Medicines Agency. Revlimid: EPAR - Product information. EMA. https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration. Revlimid (lenalidomide) prescribing information. FDA. https://www.accessdata.fda.gov/
[3] National Institutes of Health. ClinicalTrials.gov: lenalidomide trials. ClinicalTrials.gov. https://clinicaltrials.gov/
[4] International Myeloma Foundation. Multiple myeloma treatment guidelines and lenalidomide use updates. IMF. https://www.myeloma.org/
[5] World Health Organization. Cancer fact sheets and epidemiology background relevant to multiple myeloma burden. WHO. https://www.who.int/